Literature DB >> 6362802

Dantrolene.

B A Britt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6362802     DOI: 10.1007/bf03011484

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


× No keyword cloud information.
  112 in total

1.  1-[(5-arylfurfurylidene)amino]hydantoins. A new class of muscle relaxants.

Authors:  H R Snyder; C S Davis; R K Bickerton; R P Halliday
Journal:  J Med Chem       Date:  1967-09       Impact factor: 7.446

2.  Anesthesia for elective surgery in patients susceptible to malignant hyperthermia.

Authors:  J E Relton
Journal:  Int Anesthesiol Clin       Date:  1979

3.  Effects of dantrolene sodium on the excitation-contraction coupling of the mammalian and amphibian cardiac muscle.

Authors:  J Hatae; M Ohba; H Kawata
Journal:  J Mol Cell Cardiol       Date:  1980-09       Impact factor: 5.000

4.  The effects of dantrolene sodium on excretory function in the isolated perfused rat liver.

Authors:  C O Abernathy; R Utili; H J Zimmerman; M Ezekiel
Journal:  Toxicol Appl Pharmacol       Date:  1978-06       Impact factor: 4.219

5.  Malignant hyperthermia: a consideration for plastic surgeons.

Authors:  L E Dohlman
Journal:  Plast Reconstr Surg       Date:  1982-03       Impact factor: 4.730

6.  Pharmacology: dantrolene sodium.

Authors:  S Hopkins
Journal:  Nurs Mirror       Date:  1980-12-11

7.  The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration.

Authors:  W J Meyler; H Bakker; J J Kok; S Agoston; H Wesseling
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-04       Impact factor: 10.154

8.  Management of suspected malignant hyperpyrexia in an infant.

Authors:  D K Faust; S D Gergis; M D Sokoll
Journal:  Anesth Analg       Date:  1979 Jan-Feb       Impact factor: 5.108

9.  A comparison of the effects of sodium thiocyanate and dantrolene sodium on a mammalian isolated skeletal muscle.

Authors:  R F Moulds
Journal:  Br J Pharmacol       Date:  1977-01       Impact factor: 8.739

10.  Rationale for dantrolene vs. procainamide for treatment of malignant hyperthermia.

Authors:  T E Nelson; E H Flewellen
Journal:  Anesthesiology       Date:  1979-02       Impact factor: 7.892

View more
  16 in total

1.  Rewarming following hypothermic cardiopulmonary bypass in the malignant hyperthermia-susceptible patient: implications for diagnosis and perioperative management.

Authors:  G C Allen; C B Cattran
Journal:  Can J Anaesth       Date:  1989-01       Impact factor: 5.063

Review 2.  Etiopathogenetic defect of malignant hyperthermia: hypersensitive calcium-release channel of skeletal muscle sarcoplasmic reticulum.

Authors:  P J O'Brien
Journal:  Vet Res Commun       Date:  1987       Impact factor: 2.459

3.  Development of malignant hyperthermia obscured by cardiopulmonary bypass.

Authors:  R G MacGillivray; H Jann; E Vanker; L Gemmell; A E Mahomedy
Journal:  Can Anaesth Soc J       Date:  1986-07

4.  Availability of dantrolene in Canadian hospitals.

Authors:  P G Duncan
Journal:  Can Anaesth Soc J       Date:  1985-05

5.  Malignant hyperthermia.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1985-11

6.  Effect of dantrolene on KCl- or NMDA-induced intracellular Ca2+ changes and spontaneous Ca2+ oscillation in cultured rat frontal cortical neurons.

Authors:  T Hayashi; A Kagaya; M Takebayashi; T Oyamada; M Inagaki; Y Tawara; N Yokota; J Horiguchi; T P Su; S Yamawaki
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 7.  Adverse effects of neuromuscular blockers and their antagonists.

Authors:  M Naguib; M M Magboul
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

8.  Dantrolene--in vitro studies in malignant hyperthermia susceptible (MHS) and normal skeletal muscle.

Authors:  B A Britt; E Scott; W Frodis; M J Clements; L Endrenyi
Journal:  Can Anaesth Soc J       Date:  1984-03

Review 9.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

10.  Malignant hyperthermia: a possible new variant.

Authors:  D S Lee; J P Adams; J E Zimmerman
Journal:  Can Anaesth Soc J       Date:  1985-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.